CION Ameerpet
If melanoma has reached the brain, you are not out of options. Immunotherapy, targeted therapy and precise radiosurgery now control brain lesions once thought untreatable.
Being told that melanoma has spread to the brain is frightening. But this is one area of cancer care that has changed dramatically in the last decade. Melanoma is among the cancers most likely to reach the brain — yet the same modern medicines that transformed advanced melanoma, together with precise radiation, now control brain lesions that were once considered untreatable.
A melanoma brain metastasis (sometimes called a "melanoma brain met" or "skin cancer brain metastasis") is a secondary brain tumour. The cells started in the skin — occasionally the eye or a mucosal surface — and travelled through the bloodstream to the brain. Under the microscope they are still melanoma, so treatment follows what works for melanoma, not for primary brain tumours like gliomas. If you want the wider picture, see our overview of which cancers spread to the brain and the Brain Cancer & Tumour hub.
BRAF status changes the plan. Roughly 50% of cutaneous melanomas carry a BRAF mutation, which opens the door to BRAF/MEK-targeted therapy. Modern NCCN melanoma guidance supports combining systemic therapy with stereotactic radiosurgery for brain metastases — an approach that has meaningfully improved intracranial control compared with older whole-brain radiation alone.
A melanoma brain metastasis is not a new, separate cancer. It is the same melanoma that needs to be treated as one disease — in the brain and everywhere else it may be.
The brain lesions are made of melanoma cells, so they respond to melanoma-directed treatment — immune checkpoint therapy and, for BRAF-mutated tumours, BRAF/MEK-targeted therapy. This is completely different from how a primary brain tumour such as a glioma is treated. Getting the diagnosis right is the first step.
Because melanoma often spreads to more than one site, doctors treat the brain lesions and any disease elsewhere as one connected problem. Radiosurgery targets the brain precisely, while systemic therapy works throughout the body. That is why a coordinated tumour board plan matters so much.
Melanoma brain lesions have a higher tendency to bleed than some other metastases. This can cause a sudden, severe headache or a rapid change in symptoms. It is one reason a contrast brain MRI is important — and why any sudden new neurological change should be assessed urgently.
Most headaches and everyday aches are not caused by cancer. But if you have a melanoma history, certain patterns deserve prompt attention. Symptoms depend on where the lesions sit and how much swelling they cause. Watch for symptoms that are new, persistent and progressive:
Red flag: If you have had melanoma and develop any new, persistent, progressive neurological symptom, ask for an urgent contrast brain MRI. Early detection widens your treatment options. Speak to a CION oncologist if this sounds like you or someone you love.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Bring your brain MRI and BRAF report. CION's team will review them and explain your real options — immunotherapy, targeted therapy and radiosurgery — in a free 45-minute consultation.
Getting the full picture quickly is what shapes a good plan. Diagnosis has three parts: confirming the brain lesions, mapping the disease elsewhere, and testing the melanoma at a molecular level.
An MRI of the brain with gadolinium contrast is the most sensitive test for brain metastases. It shows how many lesions there are, their size, and exactly where they sit — information that directly decides between radiosurgery, surgery and whole-brain radiation. A CT scan is faster and used in emergencies (for example, a sudden severe headache or new seizure).
Because melanoma often spreads to more than one site, a PET-CT or CT of the body is usually done to map all the disease. Treating the brain in isolation is not enough — the plan has to address melanoma wherever it is. This is why care is coordinated across our brain tumour treatment and medical oncology teams.
Roughly half of skin melanomas carry a mutation in the BRAF gene. Testing for it is essential, because a BRAF mutation makes BRAF/MEK-targeted therapy an option — a treatment that can shrink brain lesions and disease elsewhere at the same time. If BRAF testing has not been done on your melanoma sample, it should be. At CION we arrange this molecular testing as part of the work-up.
There is rarely one single treatment. A multidisciplinary tumour board combines the approaches below into one plan tailored to how many lesions you have, whether melanoma is elsewhere, your BRAF status, and your general health. CION delivers radiation and systemic therapy directly; any neurosurgery is coordinated with accredited neurosurgical partners.
Despite the word "surgery," no cutting is involved. SRS delivers highly focused beams of radiation that converge on each lesion from many angles, delivering a high dose to the tumour while sparing the surrounding brain. It is the preferred treatment for a limited number of metastases, is done as an outpatient in 1–5 sessions, and increasingly is combined with immunotherapy for better intracranial control. There is no general anaesthesia and, for most patients, no hospital admission.
Immune checkpoint therapy (an immunotherapy drug class) helps your own immune system recognise and attack melanoma. It has become a cornerstone of advanced melanoma care and can act on brain lesions as well as disease elsewhere in the body. Our medical oncology team plans and delivers systemic therapy alongside the brain-directed treatment, monitoring you closely for response and side effects.
If your melanoma carries a BRAF mutation, oral BRAF/MEK-targeted therapy can shrink lesions quickly, including in the brain. It is often used where a rapid response is needed, or in combination and sequence with immunotherapy — decisions your tumour board makes for your specific situation.
Surgical removal of a lesion is considered for a large single metastasis causing pressure or symptoms, or when tissue is needed to confirm the diagnosis. CION does not perform neurosurgery in-house — we coordinate it with accredited neurosurgical partners, then continue your radiation and systemic care seamlessly.
Whole-brain radiation is reserved for widespread brain disease where focused radiosurgery is not suitable. Throughout treatment, CION provides steroid management to reduce brain swelling and anti-seizure medicine where needed, so symptoms are controlled and quality of life protected.
Combining brain-directed radiosurgery with modern melanoma systemic therapy has genuinely improved outcomes. Published studies reflected in NCCN melanoma guidance show that a meaningful share of patients now achieve durable, long-term control of brain metastases — with some living years rather than months. Outcomes still vary widely by individual, which is why an honest, personalised discussion matters.
There is no single survival number that fits everyone, and we will never offer a guarantee. Outlook depends on the number of lesions, whether melanoma is elsewhere in the body, your general health, and your BRAF status. Historically, melanoma brain metastases carried a poor prognosis.
That picture has genuinely changed. Ranges published in the literature and reflected in NCCN guidance show that combination immunotherapy together with stereotactic radiosurgery can produce durable, long-term control of brain disease in a meaningful proportion of patients — and some live years rather than months. We share these ranges honestly and sensitively, so you can make informed decisions. The aim is always to maximise both the length and the quality of your life. Your CION oncologist will explain what current evidence means for your specific situation.
For brain metastases, a second opinion is especially valuable in these situations:
CION offers a free written second opinion reviewed by a multidisciplinary tumour board. Request yours here or call 18002028726.
Melanoma is not the only cancer that can reach the brain. If your primary cancer is different — or you want to understand the wider pattern — explore these hubs:
Not sure where your care fits? Call 18002028726 and we'll connect you to the right CION team.
Get a free written second opinion from CION's tumour board — particularly valuable if BRAF testing hasn't been done, or if radiosurgery wasn't discussed as an alternative to whole-brain radiation.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Melanoma brain metastasis means melanoma cells that began in the skin (or occasionally the eye or mucosal surfaces) have travelled through the bloodstream and formed one or more new tumours in the brain. These are still melanoma under the microscope — not a primary brain tumour. That distinction matters, because treatment follows what works for melanoma, not for gliomas. Melanoma is one of the cancers most likely to reach the brain. The good news is that treatment has changed dramatically: modern immune checkpoint therapy, BRAF/MEK-targeted therapy, and precise stereotactic radiosurgery (SRS) now control many brain lesions that were once considered untreatable. A coordinated plan is decided by a tumour board.
Symptoms depend on where in the brain the lesions sit and how much swelling they cause. Warning signs include a new or steadily worsening headache (often worse in the morning or waking you from sleep), a first-ever seizure, one-sided weakness, numbness or speech difficulty, sudden vision changes, unsteadiness, or new confusion and personality change that family notice first. Melanoma metastases can also bleed, which may cause a sudden severe headache. If you have a melanoma history and develop any new, persistent, progressive neurological symptom, ask for an urgent contrast brain MRI. Early detection widens your treatment options.
The single most important test is an MRI of the brain with gadolinium contrast — it is far more sensitive than CT for small lesions and shows their number, size and location. A CT is used in emergencies. Because melanoma can spread to more than one organ, doctors also review a full staging picture (often a PET-CT) so the whole disease is treated, not just the brain. Crucially, the melanoma should be tested for a BRAF mutation — present in roughly half of cutaneous melanomas — because it decides whether targeted therapy is an option. At CION we arrange this molecular testing and review every case at a multidisciplinary tumour board.
Treatment is chosen by a tumour board and usually combines approaches. Stereotactic radiosurgery (SRS) delivers focused radiation to each lesion in 1–5 outpatient sessions and is preferred for a limited number of metastases. Immunotherapy (immune checkpoint inhibitor drug classes) and BRAF/MEK-targeted therapy (for BRAF-mutated melanoma) can shrink brain lesions and treat disease elsewhere at the same time. Neurosurgery — coordinated with accredited neurosurgical partners — is used for a large single lesion causing pressure, or to confirm the diagnosis. Whole-brain radiation is reserved for widespread disease. CION delivers the radiation and systemic therapy directly and coordinates any surgery.
Outcomes vary widely and no single number fits everyone — outlook depends on the number of lesions, whether melanoma is elsewhere in the body, your general health, and BRAF status. Historically, melanoma brain metastases carried a poor prognosis. That has genuinely improved: published studies (reflected in NCCN guidance) show that combination immunotherapy and SRS can produce durable, long-term control of brain disease in a meaningful share of patients, and some live years rather than months. We frame this honestly and sensitively — treatment is about maximising both length and quality of life, never a guarantee. Your CION oncologist will explain what the evidence means for your specific situation.
Yes. CION delivers the two pillars of modern melanoma brain-metastasis care directly: radiation therapy including precise stereotactic radiosurgery, and systemic therapy — immunotherapy and BRAF/MEK-targeted therapy — planned by our medical oncology team. We arrange BRAF molecular testing, imaging and diagnosis, and steroid and seizure management for symptom control. Any neurosurgery is coordinated with accredited neurosurgical partners. Every case is reviewed at a multidisciplinary tumour board so radiation, systemic therapy and surgery work as one plan. Care is available across CION centres in Hyderabad with a free 45-minute consultation and a written second opinion.
Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist for guidance specific to your medical condition. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines (including NCCN).
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.